Revolution Medicines (NASDAQ:RVMD) Insider Alan Sandler Sells 341 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Alan Sandler sold 341 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $67,940.84. Following the sale, the insider owned 52,868 shares of the company’s stock, valued at $10,533,420.32. This trade represents a 0.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Revolution Medicines Stock Performance

RVMD opened at $190.95 on Friday. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The firm has a market cap of $40.93 billion, a PE ratio of -21.65 and a beta of 1.40. The business has a fifty day simple moving average of $199.57 and a 200-day simple moving average of $159.57. Revolution Medicines, Inc. has a fifty-two week low of $42.18 and a fifty-two week high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the prior year, the business earned ($1.31) earnings per share. As a group, equities analysts predict that Revolution Medicines, Inc. will post -8.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on RVMD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research report on Friday, July 17th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $248.00 price objective on shares of Revolution Medicines in a research note on Thursday, August 27th. Evercore reiterated an “outperform” rating and set a $320.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 27th. Morgan Stanley initiated coverage on shares of Revolution Medicines in a research note on Thursday, September 10th. They set an “overweight” rating and a $255.00 target price on the stock. Finally, Oppenheimer raised their target price on Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $226.17.

Institutional Trading of Revolution Medicines

Several institutional investors have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC purchased a new position in shares of Revolution Medicines during the 2nd quarter valued at $626,000. MCF Advisors LLC acquired a new position in shares of Revolution Medicines in the second quarter worth $78,000. National Pension Service purchased a new stake in shares of Revolution Medicines during the second quarter worth $51,241,000. Engineers Gate Manager LP raised its holdings in shares of Revolution Medicines by 144.0% during the second quarter. Engineers Gate Manager LP now owns 7,380 shares of the company’s stock worth $1,382,000 after acquiring an additional 4,356 shares in the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in Revolution Medicines during the second quarter valued at $278,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Revolution Medicines recently received regulatory approval for a new medicine, validating its approach to treating certain cancers. The treatment could potentially become the most-prescribed therapy in its indication, improving the company’s long-term commercial outlook. Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
• Neutral Sentiment: A comparison article weighing Axsome Therapeutics against Revolution Medicines highlights RVMD as a healthcare investment candidate, but does not provide a clearly new company-specific catalyst. Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
• Negative Sentiment: Five company insiders, including the CFO and COO, collectively sold approximately $5.8 million of RVMD shares at $199.24 apiece. The filings state that the transactions were made to cover tax withholding obligations tied to vested equity awards, rather than for discretionary reasons. Nevertheless, the cluster of sales can create short-term supply and sentiment pressure. The insiders continued to hold substantial positions after the transactions. Revolution Medicines insider transaction filing

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.